

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.: OCO1000KQ	SERIAL NO.: 09/904,263
	APPLICANT: Rybak et al.	
	FILING DATE: July 12, 2001	GROUP: 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
Avh	AA	5,985,263	11/16/99	Lee et al.	424	85.2	
	AB	5,951,974	09/14/99	Gilbert et al.	424	85.7	
	AC	5,908,621	06/01/99	Glue et al.	424	85.7	
	AD	4,766,106	08/23/88	Katre et al.	514	12	
	AE	5,776,897	07/07/98	Lewis et al.	514	12	
	AF	5,766,582	06/16/98	Yuen et al.	424	85.7	
	AG	5,762,923	06/09/98	Gross et al.	424	85.7	
	AH	5,382,427	01/17/95	Plunkett et al.	424	85.2	
	AI	4,917,888	04/17/90	Katre et al.	424	85.91	
	AJ	4,897,471	01/30/90	Stabinsky	536	27	
	AK	4,695,623	09/22/87	Stabinsky	530	351	
	AL	4,530,901	07/23/85	Weissmann	435	70	
	AM	4,492,537	01/08/85	Awerkamp	417	404	
	CE	5,711,944	1/27/98	Gilbert et al.	424	85.7	
	CF	5,766,897	06/16/98	Braxton	435	172.1	
	CG	6,362,162 B1	03/26/02	Rybak et al.	514	2	
	CH	2001/0053548 A1	08/09/01	Rybak et al.	435	367	

RECEIVED

MAR 10 2003

TECH CENTER 1600/290

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
Avh	AN	0 236 987 B1	12/28/94	EPO			
	AO	0 809 996 A2	12/03/97	EPO			
	AP	0 593 868 A1	04/27/94	EPO			
	AQ	WO 99/48535	30/09/99	WIPO			
	AR	0 510 356 A1	10/28/92	EPO			
	CD	WO95/13090	05/18/95	WIPO			
	CL	WO98/48840	05/11/98	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Avh	AS	Kantarjian et al., "Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options," <i>Blood</i> 87:8 pp. 3069-3081, April 15, 1996
	AT	Hehlman et al., "Randomized Comparison of Interferon- α With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia," <i>Blood</i> 84:12 pp. 4064-4077, December 15, 1994
	AU	Kantarjian et al., "Chronic Myelogenous Leukemia: A Concise Update," <i>Blood</i> 82:3 pp. 691-703, August 1, 1993
	AV	Nicolaou et al., "Total Synthesis of Taxol. 1. Retrosynthesis, Degradation, and Reconstitution," <i>J. Am. Chem. Soc.</i> 117 pp. 624-633, 1995
Avh	AW	Hasford, et al "Interferon- α and Hydroxyurea in Early Chronic Myeloid Leukemia: A Comparative Analysis of the Italian and German Chronic Myeloid Leukemia Trials With Interferon- α ," <i>Blood</i> 87(12):5384-5391 (1996).
Avh	AX	Ozer et al., "Prolonged Subcutaneous Administration of Recombinant α 2b Interferon in Patients with Previously Untreated Philadelphia Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia: Effect on Remission Duration and Survival: Cancer and Leukemia Group B Study 8583," <i>Blood</i> 82:10 pp. 2975-2984, November 15, 1993
	AY	Ohnishi et al., "A Randomized Trial Comparing Interferon- α With Busulfan for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase," <i>Blood</i> 86:3 pp. 906-916, August 1, 1995

Anne L. Hallinan

5/17/2003



FORM PTO-1449
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

ATTY. DOCKET NO.:
OCO1000KQ
APPLICANT:
Rybak et al.
FILING DATE:
July 12, 2001
SERIAL NO.:
09/904,263
MAR 10 2003
TECH CENTER 1600/2

AH	AZ	Creagon et al., "Randomized, Surgical Adjuvant Clinical Trial of Recombinant Interferon Alfa-2a in Selected Patients With Malignant Melanoma," Journal of Clinical Oncology, 13:13 pp. 2776-2783 November 1995
I	BA	Bergmann et al., "Daily Alternating Administration of High-Dose Alpha-2b-Interferon and Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer," Cancer 72:5, pp. 1735-1742 September 1, 1993
	BB	Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58:1231-1235, September 15, 1986
	BC	Sokal et al., "Preferential Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia," Cancer 59:197-202, January 1, 1987
	BD	Fleming et al., "One-Sample Multiple Testing Procedure for Phase II Clinical Trials," Biometrics 38:143-151 March 1982
	BE	Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989
	BF	Kantarjian et al., "Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- α Therapy," Ann Intern Med 122:254-261, 1995
	BG	Talpaz et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Medicine, 114:7 April 1, 1991
	BH	Négrier et al., "Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinoma," Journal of Immunotherapy, 17:62-68 1995
	BI	Goldman, "Optimizing Treatment for Chronic Myeloid Leukemia," The New England Journal of Medicine, 337:4, pp. 270-271, July 24, 1997
	BJ	Guilhot, et al., "Interferon Alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229
	BK	The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 330:12 pp.820-825, March 24, 1994
	BL	Atzpodiën et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progressive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995
	BM	Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp. 7-17, January 1996
	BN	Atzpodiën et al., "Home therapy with recombinant interleukin-2 and interferon- α 2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990
	BO	Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 th Ed., 1990
↓	BP	Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract
AK	BQ	Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994
ALH	BR1	Deprés-Brummer et al., "A Phase II Study of Ambulatory Chronomodulated High Dose Interferon (IFN α 2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996
I	BR2	Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996
	BR3	Gittlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon- α in the Treatment of Metastatic Renal Cell Carcinoma: The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996
	BS	P. Sagaster et al., "Randomised Study Using IFN- α versus IFN- α plus coumarin and cimetidine for treatment of advanced renal cell cancer," Annals of Oncology 6:999-1003, 1995
✓	BT	D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-108, 1997

Anne C. Adelman

5/17/2003

OIP-1000KQ
MAR 04 2003

Sheet 3 of 3

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.: OCO1000KQ	SERIAL NO.: 09/904,263
	APPLICANT: Rybak et al.	
	FILING DATE: July 12, 2001	GROUP: 1642

AP	BU	Sewa S. Legha, "The Role of Interferon Alfa in the Treatment of Metastatic Melanoma," <i>Seminars in Oncology</i> , 24:1 Suppl 4 (February) 1997, pp. S4-24-54-31
	BV	W. Levens et al., "Long-Term Interferon Treatment in Metastatic Renal Cell Carcinoma," <i>Eur Urol.</i> 16:378-381, 1989
	BW	Janice P. Dutcher, et al., "Outpatient Subcutaneous Interleukin-2 and Interferon-Alpha for Metastatic Renal Cell Cancer: Five-Year Follow-up of the Cytokine Working Group Study," <i>The Cancer Journal from Scientific American</i> 3:3 May/June 1997
	BX	Talpaz et al, "Phase I Study Of Polyethylene Glycol (PEG) Interferon Alpha-2B (Intron-A) in CML Patients", <i>Blood</i> , Volume 92, Issue 10, Suppl. 1 part 1-2, 11/15, 1998, pp. 251A
	BY	Talpaz et al, "Phase I Study Of Pegylated-Interferon α -2A (PEGASYS™) In Patients With Chronic Myelogenous Leukemia (CML)", <i>Blood</i> , Vol. 94, Issue 10, Suppl. 1, part 1, 11/15, 1999, pp.530A.
	BZ	Walther P.J. et al., "Treatment of Metastatic Renal Cell Carcinoma (RCC) with Continuous Infusion 5-Fluorouracil and Interferon Alpha-2A in the Home Setting: A Phase I-II Trial", <i>Proceedings of the American Urological Association</i> , Vol. 155, May 1996 Supplement, p. 388A.
	CA	Gebrosky et al., "Treatment of Renal Cell Carcinoma with 5-Fluorouracil and Alfa-Interferon", <i>Urology</i> , 50 (6) 1997, pp. 863-868.
	CB	Atzpodien J. et al., "Interleukin-2 in Combination with Interferon- α and 5-Fluorouracil for Metastatic Renal Cell Cancer", <i>European Journal of Cancer</i> , Vol. 29A, Suppl. 5, 1993, pp. S6-S8.
AP	CM	Bukowski et al., "Pegylated Interferon Alfa-2b Treatment for Patients with Solid Tumors: A Phase I/II Study," <i>J. Clin. Oncol.</i> 20 (18) 3841-3849 (2002).
EXAMINER Anne C. Hollman		DATE CONSIDERED 5/17/2003
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

29132_1

RECEIVED
MAR 10 2003
TECH CENTER 1600/2900